GSK
GSK plc (formerly GlaxoSmithKline) is a London-headquartered global biopharmaceutical company, one of the world's top-10 prescription-drug makers, focused on vaccines, respiratory/HIV specialty medicines, and oncology. In 2023 it generated roughly £30.3bn (~$38.6bn) in revenue and is the UK's second 'big pharma' after AstraZeneca. It runs a global manufacturing network spanning sterile vaccine fill-finish (aseptic vials and prefilled syringes), Ellipta dry-powder inhaler device assembly (Ware UK; Zebulon/Marietta US), API synthesis (Montrose Scotland, Jurong Singapore), and oral solid-dose tablet plants. Leadership transitioned from Emma Walmsley (CEO 2017-2025, big pharma's first female CEO) to former chief commercial officer Luke Miels effective 1 Jan 2026. GSK is actively investing in 'smart manufacturing' (digital twins, robotics, AI) and lab automation, including a recently announced $30bn US R&D/supply-chain program with $1.2bn earmarked for advanced manufacturing, AI and digital technologies.
Recommended pilots
All use cases — ranked
● validated · ○ researched| Use case | Source | Failure tol. | Tactile | Readiness | Demand |
|---|---|---|---|---|---|
| ★Assemble Ellipta dry-powder inhaler — snap-fit closure and small-component seating ↗ | medium | high | stretch | strong | |
| De-nest, handle and stopper filled glass vials in aseptic vaccine fill-finish ↗ | low | high | stretch | promising | |
| Assemble prefilled syringes — plunger rod insertion and cap/needle-shield seating ↗ | low | high | aspirational | promising |